Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Letrozole|DRUG: Chemotherapy|DRUG: Ribociclib plus letrozole
Sponsor: Borstkanker Onderzoek Groep
Collaborators: Novartis|Philips Healthcare